Ser427

Site Information
DFNIsSHsELENSSE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 31859969

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	breast cancer ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , BT-549 (breast cell) ( 3 ) , H2009 (pulmonary) ( 3 ) , H2077 (pulmonary) ( 3 ) , H2887 (pulmonary) ( 3 ) , H322M (pulmonary) ( 3 ) , HeLa (cervical) ( 2 , 4 ) , MDA-MB-231 (breast cell) ( 3 ) , NCI-H1395 (pulmonary) ( 3 ) , NCI-H2030 (pulmonary) ( 3 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
4	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info